JP2686934B2 - In vivo lipid peroxide production inhibitor - Google Patents

In vivo lipid peroxide production inhibitor

Info

Publication number
JP2686934B2
JP2686934B2 JP18764787A JP18764787A JP2686934B2 JP 2686934 B2 JP2686934 B2 JP 2686934B2 JP 18764787 A JP18764787 A JP 18764787A JP 18764787 A JP18764787 A JP 18764787A JP 2686934 B2 JP2686934 B2 JP 2686934B2
Authority
JP
Japan
Prior art keywords
lipid peroxide
group
peroxide production
vitamin
production inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP18764787A
Other languages
Japanese (ja)
Other versions
JPS6431723A (en
Inventor
博通 加藤
グュエン・ヴァン・チュエン
章江 日高
信子 宇都宮
Original Assignee
財団法人 糧食研究会
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 財団法人 糧食研究会 filed Critical 財団法人 糧食研究会
Priority to JP18764787A priority Critical patent/JP2686934B2/en
Publication of JPS6431723A publication Critical patent/JPS6431723A/en
Application granted granted Critical
Publication of JP2686934B2 publication Critical patent/JP2686934B2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Description

【発明の詳細な説明】 (産業上の利用分野) 本発明は、生体内過酸化脂質生成抑制剤に関するもの
である。 更に詳細には、本発明は糖質とアミノ酸が加熱反応し
てなるアミノカルボニル反応生成物を有効成分とする生
体内過酸化脂質生成抑制剤に関するものである。 本発明の生体内過酸化脂質生成抑制剤は、ヒトの老化
や動脈硬化症に関連する過酸化脂質の生成蓄積を抑制す
る作用を有するので医薬界及び食品界に益するところ大
なるものがある。 (従来の技術) 一般に、生体内での過酸化脂質の生成蓄積は、ヒトの
老化(シワ、老人性色素、老眼、老人性白内障、白髪発
生)、動脈硬化症(脳卒中、狭心症、心筋梗塞)、各種
癌などに関連する傾向がみられ、その意味からも過酸化
脂質の生成蓄積を抑制する方法が注目されつつある。 従来、過酸化脂質生成抑制剤としては、ビタミンE、
ビタミンC、ビタミンA、尿酸などのラジカル消去剤や
カタラーゼ、ペルオキシダーゼ、グルタチオンペルオキ
シダーゼ、スーパーオキシドジスムターゼなどの酵素が
知られているが、脂質系での酸化反応を直接生体内で防
御している生体抗酸化剤としてはビタミンEが認められ
るだけである。 (発明が解決しようとする問題点) ビタミンEは、すぐれた過酸化脂質生成抑制効果を有
するものであるが、ビタミンEは脂溶性であり、水溶性
とはなり得ないものである。 従来、水溶性の生体内過酸化脂質生成抑制抗酸化剤は
見出されていないが、生体内過酸化脂質の生成を抑える
有効かつ安全な水溶性抗酸化剤が見出されれば、きわめ
て有用で、適用範囲が広がるものと推測される。 (問題点を解決するための手段) 本発明者らは、水溶性で安全な生体内過酸化脂質生成
抑制剤を求めて鋭意研究を進めてきたが、糖とアミノ酸
からなるアミノカルボニル反応生成物に生体内過酸化脂
質生成抑制作用のあることを見出し本発明を完成した。 本発明は、アミノカルボニル反応生成物を有効成分と
する生体内過酸化脂質生成抑制剤に関するものである。 本発明でいうアミノカルボニル反応生成物とは、アミ
ノ酸などのアミノ化合物と還元糖などのカルボニル化合
物との加熱反応生成物の総称である。 カルボニル化合物としては、グルコース、フラクトー
ス、キシロース、アラビノースなどの糖類があり、ま
た、アミノ酸としてはグリシン、ヒスチジン、アルギニ
ンなどがある。 反応は、糖類の1種または数種の組合せとアミノ酸の
1種または数種の組合せを混合し、水溶液とし、これに
重炭酸ソーダ等を少量添加し、加熱することによって、
反応液は褐変し、アミノカルボニル反応物を生成する。
加熱反応は、100℃、2時間程度でよい。 得られた反応液は凍結乾燥、噴霧乾燥等により粉末化
し、そのまま又は錠剤化して服用に供することができ
る。 次に本発明の実施例を示す。 実施例 (アミノカルボニル反応生成物の製造) アルギニン(1M)、グルコース(1M)、NaHCO3(0.1
M)を混合液の100℃2時間加熱してから凍結乾燥、粉末
化しアミノカルボニル反応生成物(以下、AC生成物とい
う)を得た。 (生体内過酸化脂質生成抑制試験) 表1 ラット用飼料 カゼイン(ビタミン含有せず) 20.0(%) コーン油(ビタミンE含有せず)* 5.0 セルロース 5.0 ミネラル混合物(ハーパー法による) 4.0 ビタミン混合物(ハーパー法による) 1.0 蔗糖 24.0 α化とうもろこし澱粉 35.0 AC生成物 6.0 100 % *E群とEC群については、α−トコフェロールアセテー
トが20ppm添加される。 体重48〜50gのWistar系雄ラット20匹を下記4群に分
け、表1の飼料で約2ヶ月間、自由摂取飼育後解剖し赤
血球を分離、ジアルル酸溶血試験を行い、同時に肝臓中
の過酸化脂質量をTBA法で測定した。 なお、ジアルル酸溶血試験は次の方法で行う。 内筒をピストンと共にノボヘパリンに湿潤させた注射
器を用い、ラットの下大静脈又は腹大動脈より2〜3ml
を採血する。採血したノボヘパリン血を3,000rpm、10分
間遠沈し、血漿と赤血球を分離する。血漿を除去したの
ち、赤血球0.5mlをピペットでとる。これに生理食塩水2
0mlを加え混和し、3,000rpm、10分間遠沈後、上清を捨
てる。赤血球層の底部より赤血球0.2mlをとり、これに
3.8mlの生理食塩水を加え、5%浮遊液として使用す
る。 まず、0.05M燐酸緩衝液、ジアルル酸溶液(0.05M燐酸
緩衝液で1mg/mlとしたもの)、赤血球浮遊液を37℃の水
溶中で、それぞれを定温化させる。 次に試験管A,B,Cの3本を用意し、全ての試験管に5
%赤血球浮遊液を250μづつとる。ついで、0.05M燐酸
緩衝液300μをAに、200μをB,Cに加える。B,Cには
さらにジアルル酸溶液を100μを加え、静かに混和
し、A,B,C全てを37℃30分間保温する。保温30分後、A,B
には混合溶液(0.05M燐酸緩衝液と生理食塩水の1:1混合
液)を5ml加え、Cには5mlの蒸溜水を加え混合し、3,00
0rpmで10分間遠沈し、上清を540nmで吸光度を測定す
る。 溶血率は次式で算出する。 なお、またTBA値の測定は、次の方法で行なう。5gの
ラット肝臓を0.1M燐酸緩衝液(pH7.4)で水中でホモゲ
ナイズし、最終容量を100mlとする。これを1,500rpm、1
0分遠心分離し、得られた上清2mlに10%TCA溶液1mlと1
%TBA溶液2mlを加え、37℃で1時間インキュベートし、
冷却後3,000rpm、10分間遠心分離し、上澄液について53
5nmで吸光度を測定する。 N群……対照(ビタミンEなし) C群……AC生成物6%添加 E群……ビタミンE20ppm添加 EC群……AC生成物6%添加+ビタミンE20ppm添加 溶血率および肝臓のTBA値を表3に示した。なお、各
群のラットの体重増加量、飼料摂取量には、有意差はな
かった。 N群とC群では、溶血率、TBA値いずれも有意にC群
の方が低い値を示した(p<0.01)。E群とEC群では、
TBA値は有意にEC群の方が低い値を示した(p<0.0
1)。 次に、ビタミンEの添加率を2ppmとした以外は同条件
でラットを2ヶ月間飼育した時の結果を表4に示した。
この場合も、N群とC群、E群とEC群では、溶血率はア
ミノカルボニル反応生成物を添加したC群、EC群の方が
有意に低い値を示した(p<0.05)。 以上の結果からビタミンE欠乏ラットにアミノカルボ
ニル反応生成物を投与することにより、赤血球の溶血率
および過酸化脂質の生成を抑制出来ることが明らかにな
った。また、ビタミンEを20ppm添加した場合は、E
群、EC群とも溶血率は低かったが、ビタミンEが微量
(2ppm)の場合はE群の赤血球溶血率は高く、アミノカ
ルボニル反応生成物を添加することにより、その溶血率
を有意に(約50%)低下出来ることが明らかとなった。
DETAILED DESCRIPTION OF THE INVENTION (Field of Industrial Application) The present invention relates to an in vivo lipid peroxide production inhibitor. More specifically, the present invention relates to an in vivo lipid peroxide production inhibitor containing an aminocarbonyl reaction product obtained by heating a sugar and an amino acid as a reaction product. The in vivo lipid peroxide production inhibitor of the present invention has an action of suppressing the production and accumulation of lipid peroxide associated with human aging and arteriosclerosis, and thus has great advantages in the pharmaceutical and food industries. . (Prior Art) In general, the production and accumulation of lipid peroxides in vivo is caused by human aging (wrinkles, senile pigments, presbyopia, senile cataracts, gray hair development), arteriosclerosis (stroke, angina, myocardium). Infarction), various cancers and the like tend to be observed, and from that point of view, methods for suppressing the production and accumulation of lipid peroxides are drawing attention. Conventionally, as a lipid peroxide production inhibitor, vitamin E,
Although radical scavengers such as vitamin C, vitamin A, and uric acid, and enzymes such as catalase, peroxidase, glutathione peroxidase, and superoxide dismutase are known, bio-antibody that directly protects the oxidation reaction in lipid system in vivo. Vitamin E is the only recognized oxidant. (Problems to be Solved by the Invention) Vitamin E has an excellent lipid peroxide production inhibitory effect, but vitamin E is fat-soluble and cannot be water-soluble. So far, no water-soluble in vivo lipid peroxide production inhibiting antioxidant has been found, but if an effective and safe water-soluble antioxidant that suppresses in vivo lipid peroxide production is found, it will be extremely useful, It is speculated that the scope of application will expand. (Means for Solving the Problems) The inventors of the present invention have conducted earnest research in search of a water-soluble and safe lipid peroxidation lipid production inhibitor, but an aminocarbonyl reaction product composed of a sugar and an amino acid. The present invention has been completed by discovering that it has an action of inhibiting lipid peroxide production in vivo. The present invention relates to an in vivo lipid peroxide production inhibitor containing an aminocarbonyl reaction product as an active ingredient. The term "aminocarbonyl reaction product" as used in the present invention is a general term for a heating reaction product of an amino compound such as an amino acid and a carbonyl compound such as a reducing sugar. Carbonyl compounds include sugars such as glucose, fructose, xylose and arabinose, and amino acids include glycine, histidine and arginine. The reaction is carried out by mixing one or several kinds of saccharides and one or several kinds of amino acids into an aqueous solution, adding a small amount of sodium bicarbonate, etc., and heating the mixture.
The reaction solution turns brown and produces an aminocarbonyl reaction product.
The heating reaction may be performed at 100 ° C. for about 2 hours. The obtained reaction solution can be powdered by freeze-drying, spray-drying, etc. and used as it is or after tableting. Next, examples of the present invention will be described. Example (Production of Aminocarbonyl Reaction Product) Arginine (1M), glucose (1M), NaHCO 3 (0.1M)
M) was heated at 100 ° C. for 2 hours, lyophilized and powdered to obtain an aminocarbonyl reaction product (hereinafter referred to as AC product). (In vivo lipid peroxide production inhibition test) Table 1 Rat feed casein (without vitamin) 20.0 (%) Corn oil (without vitamin E) * 5.0 Cellulose 5.0 Mineral mixture (by Harper method) 4.0 Vitamin mixture ( (By Harper method) 1.0 Sucrose 24.0 Pregelatinized corn starch 35.0 AC product 6.0 100% * For group E and EC, 20 ppm of α-tocopherol acetate is added. Twenty male Wistar rats weighing 48 to 50 g were divided into the following 4 groups, and the animals in the diet shown in Table 1 were dissected after free-feeding for about 2 months to separate erythrocytes, and a diallylic acid hemolysis test was performed. The amount of oxidized lipid was measured by the TBA method. The diallylic acid hemolysis test is performed by the following method. Use a syringe with the inner cylinder moistened with novoheparin together with a piston, and 2-3 ml from the rat inferior vena cava or abdominal aorta.
To collect blood. The collected blood of novoheparin is spun down at 3,000 rpm for 10 minutes to separate plasma and red blood cells. After removing the plasma, pipette 0.5 ml of red blood cells. Saline 2
Add 0 ml and mix, spin down at 3,000 rpm for 10 minutes, and discard the supernatant. Take 0.2 ml of red blood cells from the bottom of the red blood cell layer
Add 3.8 ml of physiological saline and use as a 5% suspension. First, a 0.05 M phosphate buffer solution, a dialuric acid solution (made to be 1 mg / ml with a 0.05 M phosphate buffer solution), and an erythrocyte suspension are allowed to incubate in water at 37 ° C. Next, prepare three test tubes A, B, and C, and add 5 to all test tubes.
Take 250% of each red blood cell suspension. Then, 300 μ of 0.05 M phosphate buffer is added to A, and 200 μ is added to B and C. To B and C, add 100 μl of dialylic acid solution, mix gently and keep all A, B and C at 37 ℃ for 30 minutes. After 30 minutes of heat retention, A, B
5 ml of a mixed solution (1: 1 mixture of 0.05 M phosphate buffer and physiological saline) was added to C, and 5 ml of distilled water was added to C and mixed,
Centrifuge at 0 rpm for 10 minutes, and measure the absorbance of the supernatant at 540 nm. The hemolysis rate is calculated by the following formula. The TBA value is measured by the following method. 5 g of rat liver is homogenized in 0.1 M phosphate buffer (pH 7.4) in water to a final volume of 100 ml. This is 1,500 rpm, 1
Centrifuge for 0 minutes and add 2 ml of the resulting supernatant to 1 ml of 10% TCA solution.
Add 2 ml of% TBA solution and incubate at 37 ℃ for 1 hour,
After cooling, centrifuge at 3,000 rpm for 10 minutes, and collect the supernatant 53
Absorbance is measured at 5 nm. Group N: Control (no vitamin E) Group C: 6% AC product added Group E: Vitamin E 20 ppm added EC group: 6% AC product + Vitamin E 20 ppm added Hemolysis rate and liver TBA value table Shown in 3. In addition, there was no significant difference in the weight gain and the feed intake of the rats in each group. In the N group and the C group, both the hemolysis rate and the TBA value were significantly lower in the C group (p <0.01). In group E and group EC,
The TBA value was significantly lower in the EC group (p <0.0
1). Next, Table 4 shows the results when the rats were bred for 2 months under the same conditions except that the addition rate of vitamin E was 2 ppm.
Also in this case, in the N group and the C group, and in the E group and the EC group, the hemolysis rate was significantly lower in the C group and the EC group to which the aminocarbonyl reaction product was added (p <0.05). From the above results, it was revealed that the administration of the aminocarbonyl reaction product to vitamin E-deficient rats can suppress the hemolysis rate of red blood cells and the production of lipid peroxide. Also, if 20ppm of vitamin E is added, E
Although the hemolysis rate was low in both the EC and EC groups, when the amount of vitamin E was very small (2 ppm), the red blood cell hemolysis rate in the E group was high, and the hemolysis rate was significantly (about 50%).

───────────────────────────────────────────────────── フロントページの続き (56)参考文献 特開 昭56−55396(JP,A) 特開 昭56−86198(JP,A) 特開 昭56−95197(JP,A) 特開 昭56−55397(JP,A) 特開 昭56−113792(JP,A)   ────────────────────────────────────────────────── ─── Continuation of front page    (56) References JP-A-56-55396 (JP, A)                 JP-A-56-86198 (JP, A)                 JP-A-56-95197 (JP, A)                 JP-A-56-55397 (JP, A)                 JP-A-56-113792 (JP, A)

Claims (1)

(57)【特許請求の範囲】 1.糖類とアミノ酸によるアミノカルボニル反応生成物
を有効成分とする生体内過酸化脂質生成抑制剤。
(57) [Claims] An in vivo lipid peroxide production inhibitor containing an aminocarbonyl reaction product of a saccharide and an amino acid as an active ingredient.
JP18764787A 1987-07-29 1987-07-29 In vivo lipid peroxide production inhibitor Expired - Lifetime JP2686934B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP18764787A JP2686934B2 (en) 1987-07-29 1987-07-29 In vivo lipid peroxide production inhibitor

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP18764787A JP2686934B2 (en) 1987-07-29 1987-07-29 In vivo lipid peroxide production inhibitor

Publications (2)

Publication Number Publication Date
JPS6431723A JPS6431723A (en) 1989-02-02
JP2686934B2 true JP2686934B2 (en) 1997-12-08

Family

ID=16209769

Family Applications (1)

Application Number Title Priority Date Filing Date
JP18764787A Expired - Lifetime JP2686934B2 (en) 1987-07-29 1987-07-29 In vivo lipid peroxide production inhibitor

Country Status (1)

Country Link
JP (1) JP2686934B2 (en)

Also Published As

Publication number Publication date
JPS6431723A (en) 1989-02-02

Similar Documents

Publication Publication Date Title
JPH03161444A (en) Maillard reaction inhibitor
US5428066A (en) Method of reducing elevated blood sugar in humans
EP0724877A1 (en) Mixture of fenofibrate and vitamin E and its therapeutic use
WO1990010439A1 (en) Dietary supplement for insulin-resistant diabetics
CN1297527C (en) Stabilized compositions of aqueous reduced coenzyme Q solution
RU2426552C2 (en) Extracts of phaseolus vulgaris, their application and compositions containing them
WO2005107496A1 (en) Method of producing fresh mushroom extract, extract and extract-containing material
Lazarow et al. Presence of the peroxisomal 22-kDa integral membrane protein in the liver of a person lacking recognizable peroxisomes (Zellweger syndrome).
CA2029421A1 (en) Pharmaceutical compositions and methods for inhibition of maillard&#39;s reaction
JP3610358B2 (en) Antioxidant
JP2686934B2 (en) In vivo lipid peroxide production inhibitor
JP4233029B2 (en) Maitake extract, glycoprotein, and production method thereof
JP3228534B2 (en) Composition for lowering blood alcohol concentration
JPH05271090A (en) Agent for eliminating/removing active oxygen
JP7398207B2 (en) Toxic AGEs generation inhibitor
JP2002101869A (en) Agent for protecting from dehydration stress
CN112898410A (en) Tachypleus tridentatus hemocyanin and preparation method and application thereof
JP3696898B2 (en) Hemoglobin-containing liposome
JP2020026395A (en) Anti-i type allergic agent
SE457958B (en) WATER-SOLUBLE HEMIN ARGINATE OR HEMIN-LYSINATE SOCIETY, PROCEDURE FOR PREPARING THEREOF AND USING THEREOF FOR MANUFACTURE OF MEDICAL COMPOSITIONS
JP3029902B2 (en) Serum lipid increasing agent
JP4334189B2 (en) AGE production inhibitor
JP2001114800A (en) Peptide for reducing cholesterol
US6261588B1 (en) Prophylactics and remedies for renal diseases
Berlyne et al. Trace elements in dialysis patients